![1]()
News
EHRs have no impact on inpatient heart failure clinical choices or outcomes
November 15, 2021
Relative to usual care, prognostic information at the bedside provided no advantage for heart failure care.
![1]()
News
BP Track: Blood pressure control rates dropped during pandemic
November 14, 2021
Data culled from 24 health systems showed lower rates of blood pressure control during the COVID-19 pandemic.
![1]()
News
New reports help nail down myocarditis risk with COVID-19 vaccine
October 11, 2021
Myocarditis linked to the two mRNA SARS-CoV-2 vaccines is rare, usually mild and self-limited, and a lot less likely than the usually more severe cases seen in COVID-19.
![1]()
News
Heart failure hospitalization risk lower with SGLT2 inhibitors than GLP-1 RAs
September 27, 2021
SGLT2 inhibitor versus GLP-1 RA use was associated with a significantly lower rate of hospitalization for heart failure in people with diabetes.
News
Cardiogenic shock teams again tied to lower mortality
September 23, 2021
New data suggest centers with a shock team had higher survival and lower resource use in the cardiac ICU.
![1]()
News
EMPEROR-Preserved: Empagliflozin’s HFpEF efficacy catalyzes a heart failure redefinition
September 20, 2021
Cardiologists have long defined heart failure as involving reduced or preserved ejection fraction. Results from big empagliflozin trials say forget that.
News
COVID vaccine preprint study prompts Twitter outrage
September 16, 2021
The authors’ conclusions about rates of myocarditis after COVID vaccine in boys aged 12-17 years are attacked for supposedly stoking antivaccine sentiment.
![1]()
News
PRESERVED-HF: Dapagliflozin improves physical limitations in patients with HFpEF
September 14, 2021
The SGLT2 inhibitor dapagliflozin boosted KCCQ scores and 6-minute walk distance in HFpEF patients in a 324-patient randomized trial.
![1]()
News
EMPEROR-Preserved spouts torrent of reports on empagliflozin treatment of HFpEF
August 31, 2021
The primary report from EMPEROR-Preserved on using empagliflozin to treat patients with HFpEF arrived with four other analyses published in its wake.
![1]()
News
Dapagliflozin in HFrEF may cut arrhythmias, sudden death: DAPA-HF
August 27, 2021
Response to the positive findings was tempered, however, by the post hoc nature of the analysis, choice of primary outcome, and inconsistencies between key subgroups.
